Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-01-18
2011-01-18
Sheikh, Humera N (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S451000, C424S452000, C424S464000, C424S465000, C424S474000, C424S489000
Reexamination Certificate
active
07871644
ABSTRACT:
The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.
REFERENCES:
patent: 4786508 (1988-11-01), Ghebre-Sellassi
patent: 5102668 (1992-04-01), Eichel et al.
patent: 5431920 (1995-07-01), Bechard
patent: 5445830 (1995-08-01), Ishizue et al.
patent: 5456923 (1995-10-01), Nakamichi et al.
patent: 6143326 (2000-11-01), Mockel et al.
patent: 6153220 (2000-11-01), Cumming et al.
patent: 6245353 (2001-06-01), Tritthart et al.
patent: 6359011 (2002-03-01), Bess et al.
patent: 2005/0037084 (2005-02-01), Nomura et al.
patent: 0413299 (1991-02-01), None
patent: 1 093 818 (2001-04-01), None
patent: 1093818 (2001-04-01), None
patent: 1273306 (2003-08-01), None
patent: 2015027 (1990-01-01), None
patent: 2-268178 (1990-11-01), None
patent: 3-74396 (1991-03-01), None
patent: 4-208225 (1992-07-01), None
patent: 4-327529 (1992-11-01), None
patent: 5-255075 (1993-10-01), None
patent: 6-116138 (1994-04-01), None
patent: 10-504020 (1998-04-01), None
patent: WO 96/34628 (1996-11-01), None
patent: WO00/02574 (2000-01-01), None
patent: WO 00/15261 (2000-03-01), None
patent: WO 00/43041 (2000-07-01), None
Kirk-Othmer; Encyclopedia of Chemical Technology; 4thEd.; 1997; pp. 571-590; vol. 22; Wiley-Interscience Publication.
Degussa; Röhm Pharma Polymers; viewed on Aug. 19, 2009 at: http://www.rohacell.com/en/pharmapolymers/service/literature/practical—course.Par.0001.TRow.003.TCell.003.File.tmp/pc—10—enteric.pdf.
H. M. El-Sabbagh, et al., “Effect of Some Additives on the Properties of Phenazopyridine Hydrochloride Granules and Their Corresponding Tablets”,Pharmazie, vol. 39, No. 6, pp. 404-406, (1984).
J. Karlsson, et al., “The mucus layer as a barrier to drug absorption in monolayers of human intestinal epithelial HT29-H goblet cells”,Int. J. Pharm., 99, pp. 209-218, (1993).
I. W. Kellaway, et al., “The influence of mucin on the bioavailability of tetracycline”,J. Pharm. Pharmac., 27 (4), pp. 281-283, (1975).
A. W. Larhed, et al., “Diffusion of Drugs in Native and Purified Gastrointestinal Mucus”,J. Pharm. Sci., vol. 86, No. 6, pp. 660-665, (1997).
S. J. Houston, et al., “The Absorption of the Oral Bisphosphonate Pamidronate under Different Dietary Conditions”,Br. J. Cancer, 71, Suppl. 24, 67, (1995).
H. Lennernås, et al., “Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration-Time Profile”,Pharm. Res., vol. 10, No. 6, pp. 879-883, (1993).
K. Morimoto, et al., “Effect of Hyaluronidase on the Small Intestinal Absorption of Drugs in Rats”,J. Pharmacobio-Dyn., 9, No. 6, s-58, (1986).
A. Wikman, et al., “A Drug Absorption Model Based on the Mucus Layer Producing Human Intestinal Goblet Cell Line HT29-H”,Pharm. Res., vol. 10, No. 6, pp. 843-852, (1993).
H. Asada, et al., “Absorption Characteristics of Chemically Mdified-Insulin Derivatives with Various Fatty Acids in the Small and Large Intestine”,J. Pharm. Sci., vol. 84, No. 6, pp. 682-687, (1995).
L. Hovgaard, et al., “Insulin stabilization and GI absorption”,J. Controlled Release, vol. 19, No. 1-3, pp. 99-108, (1992).
J. H. Lin, et al., “Factors Affecting Oral Absorption of Alendronate, a Potent Antiosteolytic Bisphosphonate, in Rats”,Pharm. Res., vol. 8, No. 10, Suppl., S273, (1991).
N. G.M. Schipper, et al., “Chitosans as absorption enhancers of poorly absorbable drugs 3: Influence of mucus on absorption enhancement”,Eur. J. Pharm. Sci., 8, No. 4, pp. 335-343, (1999).
M. P. Braybrooks, et al., “The effect of mucin on the bioavailability of tetracycline from the gastrointestinal tract; in vivo, in vitro correlations”,J. Pharm. Pharmac., 27, pp. 508-515, (1975).
A. W. Larhed, et al., “The Influence of Intestinal Mucus Components on the Diffusion of Drugs”,Pharm. Res., vol. 15, No. 1, pp. 66-71, (1998).
T. Usui, et al., “Sensitive determination of a novel bisphosphonate, YM529, in plasma, urine and bone by high-performance liquid chromatography with fluorescence detection”,J. Chromatogr. B, 652, pp. 67-72, (1994).
Röhm Pharma, “EUDRAGIT®E Application in the Production of Pharmaceutical Preparations”, Prospectus (Info E-1/e), pp. 2-7, 2005.
Polymeric Materials Science and Engineering; vol. 11, No. 1, Jan. 1995.
Kondo Himoru
Nakanishi Kiyo
Sako Kazuhiro
Sawada Toyohiro
Takemura Shigeo
Astellas Pharma Inc.
Sheikh Humera N
Townsend and Townsend / and Crew LLP
LandOfFree
Pharmaceutical composition for oral use with improved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for oral use with improved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for oral use with improved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2651589